Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with α1β2γ2S subunits of GABAA receptors

  • Danka Peričić
  • Dubravka Švob Štrac
  • Maja Jazvinšćak Jembrek
  • Josipa Vlainić
Original Article

Abstract

Benzodiazepines are drugs known to produce tolerance and dependence and also to be abused and co-abused. The aim of this study was to further explore the mechanisms that underlie adaptive changes in GABAA receptors following prolonged exposure to these drugs. Human embryonic kidney (HEK 293) cells stably expressing recombinant α1β2γ2s GABAA receptors were exposed for 72 h to a high concentration of diazepam (50 μM) in the absence or presence of other drugs. Radioligand binding studies were used to determine the parameters of [3H]flunitrazepam and [3H]muscimol binding sites and allosteric interactions between these sites. Prolonged treatment with diazepam increased the maximum number (Bmax) of [3H]flunitrazepam and [3H]muscimol binding sites in the membranes, and of [3H]muscimol binding sites on the surface of HEK 293 cells. There was no change in the affinity (Kd) of binding sites. The diazepam-induced increase in the Bmax value of [3H]flunitrazepam binding sites was reduced by two GABAA receptor antagonists, gabazine (1 and 10 μM) and picrotoxin (100 μM). In addition, it was reduced by cycloheximide (5 μg/ml), a protein synthesis inhibitor, and actinomycin D (7.5 μg/ml), an RNA synthesis inhibitor. Flumazenil (5 μM), the antagonist of benzodiazepine binding sites, also up-regulated [3H]flunitrazepam recognition sites. Simultaneous treatment with diazepam and flumazenil failed to produce an additive up-regulation. GABA (1 nM - 1 mM)-induced potentiation of [3H]flunitrazepam binding to membranes obtained from diazepam (50 μM)-pretreated cells was markedly reduced, suggesting functional uncoupling between GABA and benzodiazepine binding sites. The results suggest that diazepam up-regulated benzodiazepine binding sites on stably expressed GABAA receptors by stimulating their synthesis at both the transcriptional and translational levels. A comparable increase of [3H]muscimol binding sites expressed on the surface of intact HEK 293 cells suggests that internalisation of surface receptors presumably can not explain the uncoupling.

Keywords

GABAA receptor, recombinant HEK 293 cells Chronic diazepam Gabazine Picrotoxin Inhibitors of RNA and protein synthesis [3H]flunitrazepam [3H]muscimol binding 

Notes

Acknowledgements

HEK 293 cells were generously provided by Dr. David Graham from Sanofi-Synthélabo Research, France. Flumazenil and flunitrazepam were kindly donated by Dr. Peter Polc (Hoffmann-LaRoche, Basel, Switzerland). The study was supported by the Croatian Ministry of Science, Education and Sports (Project: Stress, GABA-A receptors and mechanisms of action of neuropsychoactive drugs). The skilful technical assistance of Mrs. Zlatica Tonšetić is gratefully acknowledged. Linguistic correction provided by Dr. David M. Smith is truly appreciated.

References

  1. Ali NJ, Olsen RW (2001) Chronic benzodiazepine treatment of cells expressing recombinant GABAA receptors uncouples allosteric binding: studies on possible mechanisms. J Neurochem 79:1100–1108PubMedCrossRefGoogle Scholar
  2. Barnard EA, Skolnick P, Olsen RW, Möhler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer Z (1998) International union of pharmacology. XV. Subtypes of γ-Aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291–313PubMedGoogle Scholar
  3. Bateson AN (2002) Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharmaceut Des 8:5–21CrossRefGoogle Scholar
  4. Besnard F, Even Y, Itier V, Granger P, Partiseti M, Avenet P, Depoortere H, Graham D (1997) Development of stable cell lines expressing different subtypes of GABAA receptors. J Recept Signal Transduct Res 17:99–113PubMedGoogle Scholar
  5. Biggio G, Dazzi L, Biggio F, Mancuso L, Talani G, Busonero F, Mostallino MC, Sanna E, Follesa P (2003) Molecular mechanisms of tolerance to and withdrawal of GABAA receptor modulators. Eur Neuropsychopharmacol 13:411–423PubMedCrossRefGoogle Scholar
  6. Boileau AJ, Kucken AM, Evers AR, Czajkowski C (1998) Molecular dissection of benzodiazepine binding and allosteric coupling using chimeric gamma-aminobutyric acid A receptor subunits. Mol Pharmacol 53:295–303PubMedGoogle Scholar
  7. Brown MJ, Wood MD, Coldwell MC, Bristow DR (1998) γ-Aminobutyric acidA receptor function is desensitised in rat cultured cerebellar granule cells following chronic flunitrazepam treatment. J Neurochem 71:1232–1240PubMedCrossRefGoogle Scholar
  8. Costa E, Guidotti A (1996) Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Sci 17:192–200PubMedCrossRefGoogle Scholar
  9. Costa E, Auta J, Grayson DR, Matsumoto K, Pappas GD, Zhang X, Guidotti A (2002) GABAA receptors and benzodiazepines: a role for dendritic resident subunit mRNAs. Neuropharmacology 43:925–937PubMedCrossRefGoogle Scholar
  10. Downing SS, Lee YT, Farb DH, Gibbs TT (2005) Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABAA receptors supports an allosteric model of modulation. Brit J Pharmacol 145:894–906CrossRefGoogle Scholar
  11. Farrar SJ, Whiting PJ, Bonnert TP, McKernan RM (1999) Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer. J Biol Chem 274:10100–10104PubMedCrossRefGoogle Scholar
  12. Filtz TM, Guan W, Artymyshyn RP, Facheco M, Ford C, Molinoff PB (1994) Mechanisms of up-regulation of D2L dopamine receptors by agonists and antagonists in transfected HEK-293 cells. J Pharmacol Exp Ther 271:1574–1582PubMedGoogle Scholar
  13. Friedman LK, Gibbs TT, Farb DH (1996) γ-Aminobutyric acid A receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture. Brain Res 707:100–109PubMedCrossRefGoogle Scholar
  14. Fuchs K, Zezula J, Slany A, Sieghart W (1995) Endogenous [3H]flunitrazepam binding in human embryonic kidney cell. Eur J Pharmacol Mol Pharmacol Section 289:87–95CrossRefGoogle Scholar
  15. Gallager DW, Lakoski JM, Gonsalves SF, Rauch SL (1984) Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature 308:74–77PubMedCrossRefGoogle Scholar
  16. Garattini S, Mussini E, Marcucci F, Guaitani A (1973) Metabolic studies on benzodiazepines in various animal species. In: Garattini S, Mussini E, Randall LO (eds) Benzodiazepines. Raven Press, New York, pp 75–98Google Scholar
  17. Haefely W (1986) Biological basis of drug-induced tolerance, rebound, and dependence. Contribution of recent research on benzodiazepines. Pharmacopsychiatry 19:353–361PubMedCrossRefGoogle Scholar
  18. Hollister LE, Conley FK, Britt RH, Shuer L (1981) Long-term use of diazepam. J Am Med Assoc 246:1568–1570CrossRefGoogle Scholar
  19. Holmgren P, Jones AW (2003) Coexistence and concentrations of ethanol and diazepam in post-mortem blood specimens: risk for enhanced toxicity? J Forensic Sci 48:1416–1421PubMedGoogle Scholar
  20. Hu XJ, Ticku MK (1994) Chronic benzodiazepine agonist treatment reduces functional uncoupling of the γ-aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. Mol Pharmacol 45:618–625PubMedGoogle Scholar
  21. Jatlow P, Dobular K, Bailey D (1979) Serum diazepam concentrations in overdose. Am J Clin Pathol 72:571–577PubMedGoogle Scholar
  22. Klein RL, Whiting PJ, Harris RA (1994) Benzodiazepine treatment causes uncoupling of recombinant GABAA receptors expressed in stably transfected cells. J Neurochem 63:2349–2352PubMedCrossRefGoogle Scholar
  23. Klein RL, Mascia MP, Harkness PC, Hadingham KL, Whiting PJ, Harris RA (1995) Regulation of allosteric coupling and function of stably expressed γ-aminobutyric acid (GABA)A receptors by chronic treatment with GABAA and benzodiazepine agonists. J Pharmacol Exp Ther 274:1484–1492PubMedGoogle Scholar
  24. Korpi ER, Grunder G, Lüddens H (2002) Drug interactions at GABA (A) receptors. Prog Neurobiol 67:113–159PubMedCrossRefGoogle Scholar
  25. Kulkarni SK, Ticku MK (1990) Chronic benzodiazepine antagonist treatment and its withdrawal upregulates components of GABA-benzodiazepine receptor ionophore complex in cerebral cortex of rat. Brain Res 519:6–11PubMedCrossRefGoogle Scholar
  26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  27. Maksay G, Ticku MK (1984) Pretreatment with GABA and modulatory ligands enhances GABA receptor binding. Eur J Pharmacol 104:185–188PubMedCrossRefGoogle Scholar
  28. McKernan RM, Whiting PJ (1996) Which GABA (A)-receptor subtypes really occur in the brain. Trends Neurosci 19:139–143PubMedCrossRefGoogle Scholar
  29. Medina JH, Novas ML, De Robertis E (1983) Chronic Ro 15-1788 treatment increases the number of benzodiazepine receptors in rat cerebral cortex and hippocampus. Eur J Pharmacol 90:125–128PubMedCrossRefGoogle Scholar
  30. Mehta AK, Ticku MK (1999) An update on GABAA receptors. Brain Res Brain Res Rev 29:196–217PubMedCrossRefGoogle Scholar
  31. Miller LG, Heller J, Lumpkin M, Weill CL, Greenblatt DJ, Shader RI (1990) Augmentation of GABAA receptor function by chronic exposure to GABA-neutral and GABA-negative benzodiazepine ligands in cultured cortical neurons. Biochem Pharmacol 40:1337–1344PubMedCrossRefGoogle Scholar
  32. O’Brien CP (2005) Benzodiazepine use, abuse, and dependence. J Clin Psychiat 66(Suppl 2):28–33Google Scholar
  33. Peričić D, Tvrdeić A (1993) Dihydroergosine: anticonflict effect in rats and enhancing effects on [3H]muscimol binding in the human brain post mortem. Eur J Pharmacol 235:267–274PubMedCrossRefGoogle Scholar
  34. Peričić D, Švob Štrac D, Jazvinšćak Jembrek M, Rajcan I (2003) Prolonged exposure to γ-aminobutyric acid up-regulates stably expressed recombinant α1β2γ2S GABAA receptors. Eur J Pharmacol 482:117–125PubMedCrossRefGoogle Scholar
  35. Peričić D, Lazić J, Jazvinš ćak Jembrek M, Švob Štrac D, Rajčan I (2004) Chronic exposure of cells expressing recombinant GABAA receptors to benzodiazepine antagonist flumazenil enhances the maximum number of benzodiazepine binding sites. Life Sci 76:303–317PubMedCrossRefGoogle Scholar
  36. Peričić D, Jazvinšćak Jembrek M, Švob Štrac D, Lazić J, Rajčan Špoljarić I (2005a) Enhancement of benzodiazepine binding sites following chronic treatment with flumazenil. Eur J Pharmacol 507:7–13PubMedCrossRefGoogle Scholar
  37. Peričić D, Lazić J, Švob Štrac D (2005b) Chronic treatment with flumazenil enhances binding sites for convulsants at recombinant α1β2γ2S GABAA receptors. Biomed Pharmacother 59:408–414PubMedCrossRefGoogle Scholar
  38. Pesold C, Caruncho HJ, Impagnatiello F, Berg MJ, Fritschy J-M, Guidotti A, Costa E (1997) Tolerance to diazepam and changes in GABAA receptor subunit expression in rat neocortical areas. Neuroscience 79:477–487PubMedCrossRefGoogle Scholar
  39. Primus RJ, Yu J, Xu J, Hartnett C, Meyyappan M, Kostas C, Ramabhadran TV, Gallager DW (1996) Allosteric uncoupling after chronic benzodiazepine exposure of recombinant γ-aminobutyric acid A receptors expressed in Sf9 cells: ligand efficacy and subtype selectivity. J Pharmacol Exp Ther 276:882–890PubMedGoogle Scholar
  40. Robertson JR, Treasure W (1996) Benzodiazepine abuse-Nature and extent of the problem. CNS Drugs 5:137–146Google Scholar
  41. Roca DJ, Schiller GD, Friedman L, Rozenberg I, Gibbs TT, Farb DH (1990) γ-Aminobutyric acidA receptor regulation in culture: altered allosteric interactions following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines. Mol Pharmacol 37:710–719PubMedGoogle Scholar
  42. Romero G, Pujol M, Pauwels PJ (2006) Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists. Naunyn Schmiedebergs Arch Pharmacol 374:31–39PubMedCrossRefGoogle Scholar
  43. Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci USA 102:915–920PubMedCrossRefGoogle Scholar
  44. Rudolph U, Crestani F, Möhler H (2001) GABA (A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:402–403CrossRefGoogle Scholar
  45. Sieghart W, Fuchs K, Tretter V, Ebert V, Jechlinger M, Hoger H, Adamiker D (1999) Structure and subunit composition of GABAA receptors. Neurochem Int 34:379–385PubMedCrossRefGoogle Scholar
  46. Strang J, Griffiths P, Abbey J, Gossop M (1994) Survey of use of injected benzodiazepines among drug users in Britain. Brit Med J 308:1082PubMedGoogle Scholar
  47. Urbancic M, Marczynski TJ (1989) Chronic exposure to Ro 15-1788: differential effect on flunitrazepam binding to cortex and hippocampus. Eur J Pharmacol 171:1–7PubMedCrossRefGoogle Scholar
  48. Wafford KA (2005) GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opinion Pharmacol 5:47–52CrossRefGoogle Scholar
  49. Walters RJ, Hadley SH, Morris KDW, Amin J (2000) Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nature Neuroscience 3:1274–1281PubMedCrossRefGoogle Scholar
  50. Whiting PJ (1999) The GABA-A receptor gene family: new targets for therapeutic intervention. Neurochem Int 34:387–390PubMedCrossRefGoogle Scholar
  51. Wong G, Yoshitatsu S, Skolnick P (1992) Stable expression of type I γ-aminobutyricacidA/Benzodiazepine receptors in a transfected cell line. Mol Pharmacol 42:996–1003PubMedGoogle Scholar
  52. Wong G, Lyon T, Skolnick P (1994) Chronic exposure to benzodiazepine receptor ligands uncouples the γ-aminobutyric acid type A receptor in WSS-1 cells. Mol Pharmacol 46:1056–1062PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Danka Peričić
    • 1
  • Dubravka Švob Štrac
    • 1
  • Maja Jazvinšćak Jembrek
    • 1
  • Josipa Vlainić
    • 1
  1. 1.Division of Molecular MedicineRuđer Bošković Institute, Laboratory for Molecular NeuropharmacologyZagrebCroatia

Personalised recommendations